[Skip to Navigation]
Sign In
July 25, 2017

Power Morcellators, Postmarketing Surveillance, and the US Food and Drug Administration

Author Affiliations
  • 1Department of Medicine, Division of Cardiology, University of California, San Francisco
  • 2Editor of JAMA Internal Medicine
  • 3Department of Obstretrics and Gynecology, University of California, San Francisco
  • 4Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
JAMA. 2017;318(4):325-326. doi:10.1001/jama.2017.7704

Many changes are coming to the US Food and Drug Administration (FDA) by virtue of the passage of the 21st Century Cures Act, the recent confirmation of a new commissioner, and the current administration in Washington, DC, that is inclined toward reducing regulation, a key function of this agency. The clinical community depends on high-quality evidence about medical products, and regulatory oversight is a key mechanism for ensuring collection of that evidence. This point becomes especially apparent when important data to guide care are lacking, as illustrated by the recent example of power morcellators.

Add or change institution